38.
Ebralidze A, Guibal F, Steidl U, Zhang P, Lee S, Batholdy B, Alberich-Jorda M,
Petkova V, Rosenbauer F, Huang G, Dayaram T, Klupp J, O'Brien KB, Will B,
Hoogenkamp M, Bonifer C, Tenen DG.
PU.1 expression is modulated by the balance of functional sense and antisense RNAs
regulated by a shared cis-regulatory element.
Genes Dev. 2008 (in press)
37.
Bruns I*, Steidl U*, Fischer JC, Czibere A, Kobbe G, Raschke S, Singh R, Fenk R,
Rosskopf M, Pechtel S, von Haeseler A, Wernet P, Tenen DG, Haas R, Kronenwett R.
*contributed equally
Pegylated G-CSF mobilizes CD34+ cells with different stem and progenitor subsets
and distinct functional properties in comparison with unconjugated G-CSF.
Haematologica. 2008; 93:347-355.
36.
Steidl U*, Steidl C*, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F,
Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB,
Verhaak RG, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T,
Griesinger F, Tenen DG. *contributed equally
A distal single nucleotide polymorphism alters long-range regulation of the PU.1
gene in acute myeloid leukemia.
J Clin Invest. 2007; 117:2611-20.
35.
Neukirchen J, Meier A, Rohrbeck A, Garcia-Pardillos G, Steidl U, Fenk R, Haas
R, Kronenwett R, Rohr UP.
The proteasome inhibitor bortezomib acts differently in combination with p53 gene
transfer or cytotoxic chemotherapy on NSCLC cells.
Cancer Gene Ther. 2007; 14:431-9.
34.
Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis
AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M,
Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA.
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC
chemokine ligands 4 and 7 as markers for advanced disease.
Proc Natl Acad Sci U S A. 2007; 104:1307-12.
33.
Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub
T, Meyerson M, Tenen DG, Shapiro GI, Halmos B.
Transcriptional profiling identifies cyclin D1 as a critical downstream effector
of mutant epidermal growth factor receptor signaling.
Cancer Res. 2006; 66:11389-98.
32.
Rehfeld N, Geddert H, Atamna A, Gabbert HE, Steidl U, Fenk R, Kronenwett R,
Haas R, Rohr UP.
Coexpression of fragile histidine triad and c-kit is relevant for prediction of
survival in patients with small cell lung cancer.
Cancer Epidemiol Biomarkers Prev. 2006; 15:2232-8.
31.
Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, Klippel S,
Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegué E,
Libermann TA, Delwel R, Tenen DG.
Essential role of Jun family transcription factors in PU.1 knockdown-induced
leukemic stem cells.
Nat Genet. 2006; 38:1269-77.
30.
Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R,
Kobbe G.
Sustained G-CSF plasma levels following administration of pegfilgrastim fasten
neutrophil reconstitution after high-dose chemotherapy and autologous blood stem
cell transplantation in patients with multiple myeloma.
Exp Hematol. 2006; 34:1296-302.
29.
Kronenwett R, Gräf T, Neumann F, Pechtel S, Steidl U, Diaz-Blanco E, Haas R.
Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor
cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.
Leuk Res. 2006; 30:1323-4.
28.
Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer
J, Scheid C, Hübel K, Haas R, Kobbe G.
A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell
mobilization results in similar yields of CD34+ progenitors in patients with
multiple myeloma.
Transfusion. 2006; 46:180-5.
27.
Rehfeld N, Geddert H, Atamna A, Rohrbeck A, Garcia G, Kliszewski S,
Neukirchen J, Bruns I, Steidl U, Fenk R, Gabbert HE, Kronenwett R, Haas R, Rohr
UP.
The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of
patients with small cell lung cancer and non-small cell lung cancer.
J Carcinog. 2006; 5:4.
26.
Graef T, Steidl U, Nedbal W, Rohr U, Fenk R, Haas R, Kronenwett R.
Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis.
Angiogenesis. 2005; 8:361-72.
25.
Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL, Clayton LK,
Wagner K, Scheller M, Iwasaki H, Liu C, Hackanson B, Akashi K, Leutz A, Rothstein
TL, Plass C, Tenen DG.
Lymphoid cell growth and transformation are suppressed by a key regulatory
element of the gene encoding PU.1.
Nat Genet. 2006; 38:27-37.
24.
Koschmieder S, Rosenbauer F, Steidl U, Owens BM, Tenen DG.
Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and
leukemia.
Int J Hematol. 2005; 81:368-77.
23.
Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C,
Hildebrandt B, Haas R, Heyll A, Kobbe G; the West German Myeloma Study Group.
High-dose idarubicin, cyclophosphamide and melphalan as conditioning for
autologous stem cell transplantation increases treatment-related mortality in
patients with multiple myeloma: results of a randomised study.
Br J Haematol. 2005; 30:588-94.
22.
Steidl U, Schroeder T, Steidl C, Kobbe G, Graef T, Bork S, Pechtel S,
Kliszewski S, Kuendgen A, Rohr UP, Fenk R, Schroeder M, Haase D, Haas R,
Kronenwett R.
Distinct gene expression pattern of malignant hematopoietic stem and progenitor
cells in polycythemia vera.
Ann N Y Acad Sci. 2005; 1044:94-108.
21.
Rosenbauer F, Koschmieder S, Steidl U, Tenen DG.
Effect of transcription-factor concentrations on leukemic stem cells.
Blood. 2005; 106:1519-24.
20.
Rohr UP, Heyd F, Neukirchen J, Wulf MA, Queitsch I, Kroener-Lux G, Steidl U,
Fenk R, Haas R, Kronenwett R.
Quantitative real-time PCR for titration of infectious recombinant AAV-2
particles.
J Virol Methods. 2005; 127:40-5.
19.
Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke
A, Haas R, Kobbe G.
Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for
graft-versus-host disease prophylaxis after stem cell transplantation from
HLA-identical siblings.
Bone Marrow Transplant. 2005; 35:1089-93.
18.
Kronenwett R, Butterweck U, Steidl U, Kliszewski S, Neumann F, Bork S, Blanco
ED, Roes N, Gräf T, Brors B, Eils R, Maercker C, Kobbe G, Gattermann N, Haas R.
Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and
progenitor cells in chronic myelogenous leukemia.
Oncogene. 2005; 24:5313-24.
17.
Kobbe G, Fenk R, Neumann F, Bernhardt A, Steidl U, Kondakci M, Graef T,
Aivado M, Vaupel M, Huenerlituerkoglu AN, Kronenwett R, Pape H, Hildebrand B,
Germing U, Haas R.
Transplantation of allogeneic CD34+-selected cells followed by early T-cell
add-backs: favorable results in acute and chronic myeloid leukemia.
Cytotherapy. 2004; 6:533-42.
16.
Rohr UP, Rehfeld N, Geddert H, Pflugfelder L, Bruns I, Neukirch J, Rohrbeck
A, Grote HJ, Steidl U, Fenk R, Opalka B, Gabbert HE, Kronenwett R, Haas R.
Prognostic relevance of fragile histidine triad protein expression in patients
with small cell lung cancer.
Clin Cancer Res. 2005; 11:180-5.
15.
Neumann F, Teutsch N, Kliszewski S, Bork S, Steidl U, Brors B, Schimkus N,
Roes N, Germing U, Hildebrandt B, Royer-Pokora B, Eils R, Gattermann N, Haas R,
Kronenwett R.
Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+
hematopoietic stem and progenitor cells of patients with Ph-positive CML in major
molecular remission during therapy with imatinib.
Leukemia. 2005; 19:458-60.
14.
Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Gräf T, Rohr UP,
Bork S, Kronenwett R, Haas R, Kobbe G.
Successful transplantation of peripheral blood stem cells mobilized by
chemotherapy and a single dose of pegylated G-CSF in patients with multiple
myeloma.
Bone Marrow Transplant. 2005; 35:33-6.
13.
Fenk R, Hoyer B, Steidl U, Kondakci M, Graef T, Heuk R, Ruf L, Strupp C,
Neumann F, Rohr UP, Hildebrandt B, Haas R, Kobbe G.
Single-agent thalidomide for treatment of first relapse following high-dose
chemotherapy in patients with multiple myeloma.
Leukemia. 2005; 19:156-9.
12.
Rohr UP, Rehfeld N, Pflugfelder L, Geddert H, Müller W, Steidl U, Fenk R,
Gräf T, Schott M, Thiele KP, Gabbert HE, Germing U, Kronenwett R, Haas R.
Expression of the tyrosine kinase c-kit is an independent prognostic factor in
patients with small cell lung cancer.
Int J Cancer. 2004; 111:259-63.
11.
Fenk R, Ak M, Kobbe G, Steidl U, Arnold C, Korthals M, Hünerlitürkoglu A,
Rohr UP, Kliszewski S, Bernhardt A, Haas R, Kronenwett R.
Levels of minimal residual disease detected by quantitative molecular monitoring
herald relapse in patients with multiple myeloma.
Haematologica. 2004; 89:557-66.
10.
Steidl U, Bork S, Schaub S, Selbach O, Seres J, Aivado M, Schroeder T, Rohr
UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Bornstein SR, Haas HL, Kobbe G,
Tenen DG, Haas R, Kronenwett R.
Primary human CD34+ hematopoietic stem and progenitor cells express functionally
active receptors of neuromediators.
Blood. 2004; 104:81-8.
9.
Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl U, Fenk R, Opalka B, Pitschke G,
Prisack HB, Bojar H, Haas R, Kronenwett R.
Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a
recombinant adeno-associated virus type-2 vector.
Cancer Gene Ther. 2003; 10:898-906.
8.
Steidl U, Kronenwett R, Martin S, Haas R.
Molecular biology of hematopoietic stem cells.
Vitam Horm. 2003; 66:1-28.
7.
Steidl U, Kronenwett R, Haas R.
Differential gene expression underlying the functional distinctions of primary
human CD34+ hematopoietic stem and progenitor cells from peripheral blood and
bone marrow.
Ann N Y Acad Sci. 2003; 996:89-100.
6.
Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R.
Fast and reliable titration of recombinant adeno-associated virus type-2 using
quantitative real-time PCR.
J Virol Methods. 2002; 106:81-8.
5.
Kronenwett R, Gräf T, Nedbal W, Weber M, Steidl U, Rohr UP, Möhler T, Haas R.
Inhibition of angiogenesis in vitro by alphav integrin-directed antisense
oligonucleotides.
Cancer Gene Ther. 2002; 9:587-96.
4.
Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P,
Aivado M, Koch J, Modlich O, Bojar H, Gattermann N, Haas R.
Gene expression profiling identifies significant differences between the
molecular phenotypes of bone marrow-derived and circulating human CD34+
hematopoietic stem cells.
Blood. 2002; 99:2037-44.
3.
Steidl U, Haas R, Kronenwett R.
Intercellular adhesion molecular 1 on monocytes mediates adhesion as well as
trans-endothelial migration and can be downregulated using antisense
oligonucleotides.
Ann Hematol. 2000; 79:414-23.
2.
Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G.
A theoretical approach to select effective antisense oligodeoxyribonucleotides at
high statistical probability.
Nucleic Acids Res. 1999; 27:4328-34.
1.
Kronenwett R, Steidl U, Kirsch M, Sczakiel G, Haas R.
Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced
by cationic lipids and depends on the hematopoietic cell subset.
Blood. 1998; 91:852-62.